Simulated Clinical Use Testing to Evaluate Sharps Injury Prevention Features of HTL-STREFA's Safety Lancets (Test C)
17. juni 2021 opdateret af: HTL-Strefa S.A.
A simulated clinical use testing to evaluate the Medlance Plus and myLance sharps injury prevention feature in accordance with the FDA's guidance on medical devices with sharps injury prevention features.
Studieoversigt
Detaljeret beskrivelse
This study aims to evaluate the safety of the use of the following safety lancets: Medlance Plus and myLance in the prevention of needle-stick injury (NSI) and to evaluate the user's opinion with regard to the handling characteristics of the medical devices.
The simulated use clinical study involves healthcare professionals (HCPs) who routinely use safety lancets to collect blood samples.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
20
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60606
- Chicago office
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02116
- Boston office
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- evaluators who routinely use safety lancets to collect capillary blood samples (prevention of the learning curve artifacts)
- evaluators will be United States (US) residents
- evaluators can read, write, and speak English
- evaluators are at least 18 years old
- evaluators are able to understand and provide signed consent for the study
- evaluators are willing to comply with the study protocol, including being willing to answer questions and complete questionnaires.
- evaluators have no concerns about the ability to perform the simulated skin pricking.
Exclusion Criteria:
- evaluators who do not routinely use safety lancets to collect capillary blood samples,
- evaluators who cannot read, write, and speak English,
- evaluators or a family member have a business or consulting relationship with a pharmaceutical or medical device company, or
- evaluators who have participated in a product evaluation or marketing study involving safety lancets within the last six months
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Andet: Simulation of skin pricking by using Medlance Plus
Estimation of the true failure rate of the device.
Estimation of the sharps' injury prevention feature of the tested safety lancets are effective in preventing needle stick injuries.
|
There are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.
|
|
Andet: Simulation of skin pricking by using myLance
Estimation of the true failure rate of the device.
Estimation of the sharps' injury prevention feature of the tested safety lancets are effective in preventing needle stick injuries.
|
There are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The true failure rate of the tested devices.
Tidsramme: At time of testing, up to 90 minutes
|
At time of testing, up to 90 minutes
|
|
|
Effectiveness of the safety lancet's sharps injury prevention features.
Tidsramme: At time of testing, up to 90 minutes
|
Evaluator questionnaire using five-point response Likert scale (coded from 1 "strongly disagree" to 5 "strongly agree") to measure respondents' attitudes to a particular question or statement.
Numbers assigned to Likert scale express a "greater than" relationship.
|
At time of testing, up to 90 minutes
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Evaluation of the safety of the devices based on the evaluators' assessments.
Tidsramme: At time of testing, up to 90 minutes ]
|
At time of testing, up to 90 minutes ]
|
|
Evaluation of various aspects of the ease of use.
Tidsramme: At time of testing, up to 90 minutes ]
|
At time of testing, up to 90 minutes ]
|
|
Detection of any handling, usability questions / issues associated with the device.
Tidsramme: At time of testing, up to 90 minutes ]
|
At time of testing, up to 90 minutes ]
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
24. september 2019
Primær færdiggørelse (Faktiske)
24. september 2019
Studieafslutning (Faktiske)
27. september 2019
Datoer for studieregistrering
Først indsendt
9. juni 2021
Først indsendt, der opfyldte QC-kriterier
17. juni 2021
Først opslået (Faktiske)
21. juni 2021
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
21. juni 2021
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
17. juni 2021
Sidst verificeret
1. juni 2021
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- Test C
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .